---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-011922"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2026-03-20T23:59:59+00:00"
generated_at: "2026-05-15T09:32:47.546725+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ernexa Therapeutics receives Nasdaq delisting bid-price notice; ineligible for cure due to prior reverse split

## Summary
- Received Nasdaq notice on March 18, 2026 for failure to maintain $1.00 minimum bid price for 30 consecutive business days.
- Company not eligible for standard 180-day compliance period under Rule 5810(c)(3)(A)(iv) due to reverse stock split within past year.
- Intends to request hearing before Nasdaq Hearing Panel; request stays suspension/delisting pending panel decision and possible 180-day extension.
- No assurance that panel will grant extension or that securities (ERNA, ERNAW) will remain listed on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001493152-26-011922
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2026-03-20T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-011922
- JSON: https://secwatch.observer/filing/0001493152-26-011922.json
- Plain text: https://secwatch.observer/filing/0001493152-26-011922.txt

## Source-grounded claims
- claim_id: 12405d8e0fe58974b7678c9ad7b0983ce11c623e
  claim: Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).
  evidence_excerpt: March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”, or “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2) (the “ Rule ”). While companies are typically afforded a 180-calendar day compliance period, as specified under Nasdaq L
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000149315226011922/0001493152-26-011922-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.